Argenx Shares Plunge Sixteen Percent After Phase Two Sjögren's Disease Trial Halted

Investing.com News•Published: Oct 8, 2026 01:09 PM IST

Biotechnology company Argenx saw its shares plummet by 16% following the abrupt discontinuation of its Phase 2 clinical trial for efgartigimod in treating Sjögren's disease. The decision came after an evaluation indicated that the trial was unlikely to meet its primary efficacy endpoints, prompting the company to redirect its resources elsewhere. Management confirmed that the setback will not impact ongoing clinical evaluations of the drug in other autoimmune indications.

Efficacy Endpoint: Independent analysis revealed the trial would likely fail to achieve its pre-specified primary goals.
Stock Reaction: Investor sentiment turned sharply negative, triggering a 16% plunge in share value during trading.
Pipeline Focus: Company leadership stated that development efforts will now concentrate on other promising autoimmune disease programs.

The Context & Background

The discontinuation marks a significant hurdle for Argenx's broader autoimmune pipeline strategy, which heavily relies on expanding the label for its flagship drug, efgartigimod. Sjögren's disease is a chronic autoimmune disorder affecting moisture-producing glands, representing a notoriously difficult therapeutic target for drug developers.

Why it matters:The clinical trial failure deals a heavy blow to Argenx's portfolio expansion plans and highlights the high risks associated with targeting complex autoimmune diseases. For investors and industry watchers, the sharp stock sell-off underscores how sensitive biotech valuations remain to mid-stage pipeline setbacks.

Enjoyed this 2-minute breakdown?

Share it with your colleagues and friends!